角色交换――探索集中的依赖性对抗性与对抗性行为的整合因子联体
Beatrice Stefanie Ludwig1,2, Nils Krautkremer3, Stefano Tomassi4
1Department of Nuclear Medicine, School of Medicine & Health, Klinikum rechts der Isar, TUM University Hospital, Technical University of Munich, Ismaninger Strasse 22, Munich 81675, Germany.
Journal of medicinal chemistry
|February 5, 2025
概括
癌症整合素连接体表现出复杂的度依赖的效应. 一些配体,如西伦吉提德,可以在低剂量下意外地促进血管生成,而另一些则表现出双重的激动和对抗功能,需要对治疗用途进行仔细评估.
科学领域:
- 整体生物学 整体生物学
- 癌症治疗方法 癌症治疗方法
- 分子信号传递是分子信号传递.
背景情况:
- 整合素是癌症治疗中的关键标,导致特定抑制性连接体的发展.
- 由于在低度下促进血管生成,西伦吉提德的临床失败促使人们仔细研究纯带对抗性.
研究的目的:
- 评估整合素连接体 (αvβ3,αvβ6,α5β1) 对癌细胞的度依赖功能作用.
- 研究信号通路 (FAK,ERK) 和细胞迁移对这些配体的反应.
主要方法:
- 评估了整合素配体 (L1,L2,L3,L5) 对它们对特定整合素亚型 (αvβ3,αvβ6,α5β1) 过度表达癌细胞的影响.
- 对焦粘附激酶 (p-FAK) 和p44/42细胞外信号调节激酶 (p-p44/42 ERK1/2) 的监测酸化.
- 在不同度的细胞迁移中评估了由连接体诱导的变化.
主要成果:
- 利化物 (L2) 和L1在低度时诱导过渡信号变化,在高度时抑制细胞迁移,但在低度时加速细胞迁移.
- L5 (α5β1连接体) 显示了钟形的FAK激活,并在特定细胞中高度阻断了迁移.
- L3 (αvβ6连接体) 显示了暂时的FAK激活,但对细胞运动性没有显著影响.
结论:
- 整合素配体活性依赖于度,并且可以表现出复杂的功能开关,包括对抗和对抗效应.
- 这些发现突出了对连接体作用的彻底评估的关键需求,以优化它们在癌症治疗中的医学应用.
- 了解这些细微的影响对于开发安全有效的整体向癌症治疗至关重要.
相关概念视频
01:15Activation of Integrins
3.3K
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
3.3K
01:10Integrins
3.8K
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
3.8K
01:17Intracellular Signaling Affects Focal Adhesions
2.5K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.5K
01:29The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
01:25Drug-Receptor Interaction: Agonist
2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K
01:28Drug-Receptor Interaction: Antagonist
2.7K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
2.7K